相关临床试验
0
0 进行中
药物批准
244
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- TelyRx, a vertically integrated digital pharmacy platform serving over 97% of the U.S. population with 350+ medications, has entered into a definitive agreement with Apolo V Acquisition Corp for a go-public transaction. - The business combination includes a concurrent $40 million private placement led by Canaccord Genuity Corp, with the resulting company planning to list on the Toronto Stock Exchange. - TelyRx reported total revenue of $28.6 million for the nine months ended September 30, 2025, compared to $9.5 million for the full year 2024, demonstrating significant growth in its digital healthcare platform. - The transaction will create TelyRx Holdings Inc., led by CEO Vanessa Slowey and a management team with extensive experience in healthcare technology and pharmacy operations.
- The FDA has approved updated COVID-19 vaccines for 2025-2026 but restricted their use to adults 65 and older and individuals with risk factors for severe COVID-19. - CVS Pharmacy cannot offer COVID-19 vaccines in 16 states including New York due to regulatory requirements and is awaiting CDC approval through ACIP recommendations. - Both CVS and Walgreens are limiting vaccine offerings to comply with state pharmacy laws and federal regulations, creating a patchwork of availability across the United States. - Access to the new vaccines depends on decisions by federal health advisers, health insurers, pharmacies, and state authorities, potentially delaying availability for weeks.
